| Literature DB >> 35134898 |
Michel Haissaguerre1,2,3, Ghassen Cheniti1,2,3, Meleze Hocini1,2,3, Frederic Sacher1,2,3, F Daniel Ramirez1,2, Hubert Cochet1,2,3, Laura Bear2,3, Romain Tixier1,2,3, Josselin Duchateau1,2,3, Rick Walton2,3, Elodie Surget2,3, Tsukasa Kamakura1,2, Hugo Marchand1,2, Nicolas Derval1,2,3, Pierre Bordachar1,2,3, Sylvain Ploux1,2,3, Takamitsu Takagi1,2, Thomas Pambrun1,2,3, Pierre Jais1,2,3, Louis Labrousse2, Mark Strik1,2,3, Hiroshi Ashikaga4, Hugh Calkins4, Ed Vigmond2,5, Koonlawee Nademanee6, Olivier Bernus1,2,3, Remi Dubois1,2,3.
Abstract
AIMS: Mapping data of human ventricular fibrillation (VF) are limited. We performed detailed mapping of the activities underlying the onset of VF and targeted ablation in patients with structural cardiac abnormalities. METHODS ANDEntities:
Keywords: Ablation; Brugada syndrome; Cardiomyopathy; Purkinje system; Sudden cardiac death; Ventricular fibrillation
Mesh:
Year: 2022 PMID: 35134898 PMCID: PMC8934691 DOI: 10.1093/eurheartj/ehab893
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 29.983
Clinical data and characteristics of ventricular fibrillation episodes
| All group | Ischaemic cardiomyopathy | Non-ischaemic cardiomyopathy | Brugada syndrome |
| |
|---|---|---|---|---|---|
| Clinical characteristics | |||||
| Age at referral | 50 ± 16 | 63 ± 8 | 45 ± 16 | 45 ± 11 | <0.001 |
| Male sex no (%) | 50 (93%) | 14 (93%) | 17 (85%) | 19 (100%) | 0.20 |
| Family history of SCD | 10 | 1 | 3 | 6 | 0.157 |
| Time from diagnosis of CVD to inclusion (years) | 4.2 ± 5.9 | 3.2 ± 5.1 | 4.4 ± 7.1 | 5.1 ± 5.0 | 0.72 |
| Patients previously implanted with ICD | 33 | 4 | 12 | 17 | 0.001 |
| Time from diagnosis of CVD to ICD implantation (years) | 3.8 ± 5.5 | 4.5 ± 6.4 | 2.5 ± 5.2 | 2.2 ± 2.2 | 0.61 |
| Pts with a single clinical VF | 13 | 5 | 6 | 2 | 0.224 |
| Pts with recurrent clinical VF (median-IQR no of VF) | 41 (7 4; 16) | 10 (16 7.8; 20.3) | 14 (5 3.5; 7) | 17 (8 3; 9) | 0.224 |
| Pts with VF storm (≥3 in 24 h) | 16 (30%) | 8 (53%) | 2 (11%) | 6 (29%) | 0.021 |
| Trigger documentation on ECG | 14 pts | 8 pts | 4 pts | 2 pts | 0.014 |
| VF episodes | |||||
| Patients with no spontaneous or induced VF | 2 pts | 0 pt | 2 pts | 0 pt | 0.171 |
| No of episodes | 61[ | 19 | 19[ | 23 | 0.67 |
| Spontaneous VF | 10 | 8 | 0 | 2 | <0.001 |
| Pacing-induced episodes | 51 | 11 | 19 | 21 | 0.012 |
| Induction site: RV vs. LV | 34/17 | 7/4 | 10/9 | 17/4 | 0.161 |
| Induction mode: | |||||
| Programmed stimulation | 41 | 7 | 16 | 18 | 0.285 |
| Burst pacing | 10 | 4 | 3 | 3 | |
| Total episode duration (s) | 16.3 ± 4.4 | 15.5 ± 4.6 | 15.7 ± 3.5 | 17.3 ± 4.8 | 0.18 |
| No of VF episodes with initial organization | 56 | 16 | 18 | 22 | 0.346 |
| Duration of organized VF (s) | 5.0 ± 3.4 | 4.1 ± 1.9 | 4.6 ± 2.7 | 5.7 ± 4.6 | 0.2 |
| VF cycle length 0–2 s (ms) | 205 ± 27 | 218 ± 26 | 207 ± 25 | 196 ± 27 | 0.12 |
| VF cycle length 2–4 s (ms) | 190 ± 23 | 206 ± 21 | 191 ± 20 | 178 ± 23 | 0.008 |
| VF cycle length 8–10 s (ms) | 180 ± 23 | 199 ± 18 | 178 ± 20 | 169 ± 24 | 0.004 |
| Trigger and Purkinje mapping | |||||
| Trigger mapped (no pts) | 14 | Purkinje: 7 | Purkinje: 2 | Myocardial: 2 | |
| Repetitive Purkinje activity at induced VF (no pts) | 6 | 6 patients (37%) out of 16 pts mapped | 0 patient out of 8 pts mapped | ||
| Purkinje system implicated as a trigger or driver (no pts) | 15 | 7 | 8 | 0 | |
| Driver areas | |||||
| No and location of driver areas during organized VF | One area in 1 episode (2%) | LV in 1 (6%) | LV and IVR in 7 (39%) | RV and IVR in 15 (68%) | <0.001 |
| Driver area of focal activitiesb | 10 episodes (18%) | 2 (12%) | 0 | 8 (36%) | 0.003 |
| Catheter ablation | |||||
| No of patients | 41 pts | 10 pts | 14 pts | 17 pts | |
| Median no of VF (prior to ablation) | 7 (4–16) | 15.5 (9–20.3) | 5 (3.3–7) | 8 (3–9) | 0.057 |
| Catheter approaches: no pts | Endocardial: 26 | Endocardial: 10 | Endocardial: 14 Epicardial: 6 | Endocardial: 2 Epicardial: 17 | <0.001 |
Data are presented as n (%) or mean ± standard deviation or median [interquartile range (IQR)] as appropriate. P-value < 0.05 is considered significant. ICD, implantable cardioverter-defibrillator; VF, ventricular fibrillation; IVR, interventricular region; LV, left ventricle; pts, patients; RV, right ventricle; SCD, sudden cardiac death; CVD, cardiovascular disease.
Sixty-one VF episodes were mapped in 52 out of 54 patients; the remaining two patients (one each with hypertrophic and dilated cardiomyopathy) had no spontaneous or inducible VF.
Area of focal activities included in the driver areas as defined in the text.
Individual ablation results
| SHD | Sex | Age | #vf prior to ablation | Trigger | Substrate | RF delivery, min | VF inducible | Reablation (timing in months) | Total FU in months | Cause of death | Drug at last FU | VF recurrence (timing of 1st VF in months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Isch CM | M | 65 | 31 | Purkinje | LV | 42 | VT Induc | 105 | BB | No VF 1 VT | ||
| Isch CM | M | 61 | 18 | Purkinje | 14 | NT | 104 | No VF 1 VT | ||||
| Isch CM | M | 64 | 15 | Purkinje | LV | 37 | NT | VT abl at 12 m | 86 | Non-CV | BB | No VF |
| Isch CM | F | 74 | 7 | LV | 22 | NT | 82 | BB | No VF | |||
| Isch CM | M | 71 | 15 | Purkinje | LV | 33 | NT | 1 | VF + HF | >3 VF (1 m) | ||
| Isch CM | M | 70 | 31 | Purkinje | LV | 68 | NT | 1 | VF + HF | 23 VF (1 m) | ||
| Isch CM | M | 57 | 16 | Purkinje | LV | 29 | N Induc | 45 | BB | No VF | ||
| Isch CM | M | 54 | 4 | Myocardial | LV | 40 | N Induc | 45 | BB | No VF | ||
| Isch CM | M | 63 | 21 | Purkinje | 15 | NT | 34 | BB | 1 VF (17 m) | |||
| Isch CM | M | 43 | 3 | LV | 45 | Induc | 23 | MI + HF | >2VF (4 m) | |||
| DCM | F | 23 | 3 | Myocardial | LV | 35 | NT | 51 | BB | No VF | ||
| DCM | M | 65 | 5 | LV + RV | 50 | N Induc | 44 | Non-CV | BB | No VF | ||
| DCM | M | 74 | 7 | LV | 45 | Induc | 10 | Cancer | >2 VF (8 m) | |||
| DCM | M | 53 | 8 | LV + Purkinje[ | 20 | NT | 29 | Post-transpl | >6 VF (16 m) | |||
| DCM | F | 65 | 16 | LV + RV | 23 | NT | 33 | BB | 1 VF (1 m) | |||
| DCM | H | 35 | 3 | Myocardial | LV + RV | 38 | NT | 26 | No VF | |||
| HCM | M | 10 | 6 | Purkinje | 5 | NT | 102 | BB | 1 VF (92 m) | |||
| HCM | F | 17 | 2 | Purkinje | 9 | NT | 101 | BB | No VF | |||
| HCM | F | 24 | 12 | Purkinje[ | 18 | Induc | 99 | BB | No VF | |||
| HCM | M | 16 | 3 | LV | 55 | Induc | 52 | BB | 11 VF (1 m) | |||
| HCM | M | 50 | 5 | Purkinje[ | 42 | NT | 48 | BB Amio | 1 VF (29 m) | |||
| HCM | M | 63 | 5 | Purkinje[ | 48 | N Induc | 23 | No | No VF | |||
| HCM | M | 58 | 4 | LV | 27 | Induc | 22 | BB | No VF | |||
| HCM | M | 29 | 7 | Purkinje[ | 21 | N Induc | 12 | BB | No VF | |||
| BrS | M | 41 | 8 | RV | 57 | NT | 51 | HQuin | 3 VF (12 m) | |||
| BrS | M | 52 | 2 | RV | 20 | NT | 101 | HQuin | 2 VF (6 m) | |||
| BrS | M | 32 | 3 | RV | 22 | N Induc | 59 | No VF | ||||
| BrS | M | 32 | 5 | RV | 21 | Induc | 95 | 1 VF (23 m) | ||||
| BrS | M | 39 | 9 | RV | 34 | NT | VF abl at 66 m | 57 | HQuin | 2 VF (6 m) | ||
| BrS | M | 35 | 8 | RV | 12 | VT LV | VF abl at 30 m | 60 | No VF | |||
| BrS | M | 45 | 2 | RV | 29 | Induc | 54 | No VF | ||||
| BrS | M | 48 | 4 | RV | 30 | Induc | VT abl at 73 m | 90 | No VF | |||
| BrS | M | 63 | 2 | RVOT | 11 | NT | VPB abl at 6 m | 105 | No VF | |||
| BrS | M | 29 | 8 | RV | 16 | Induc | 62 | HQuid | 2 VF (16 m) | |||
| BrS | M | 59 | 3 | RVOT | 10 | VT Induc | 54 | No VF | ||||
| BrS | M | 56 | 20 | RV | 29 | Induc | 58 | No VF | ||||
| BrS | M | 35 | 46 | RV | 21 | N Induc | VF abl at 37 m | 36 | No VF | |||
| BrS | M | 32 | 23 | RV | 12 | VT Induc | 59 | No VF | ||||
| BrS | M | 60 | 5 | RV | NT | 54 | No VF | |||||
| BrS | M | 46 | 8 | RV | 23 | N Induc | 62 | No VF | ||||
| BrS | M | 53 | 24 | RV + LV | 62 | Induc | 50 | HQuin | 2 VF (11 m) | |||
| 35M (85%) | 47.7 ± 17 years | Mean 10.4 ± 9.8 | 29.8 ± 15.6 | VF abl in 3 pts | 55.7 ± 30.2 | No VF recurrence in 25 pts (61%) |
Group results are presented as mean ± standard deviation or median [interquartile range (IQR)]. CL, cycle length; RF, radiofrequency; RV, right ventricle; pts, patients; m, months; LV, left ventricle; VF, ventricular fibrillation; NT non-tested; CV, cardiovascular; BB, beta-blocker; HQUIN, hydroquinidine; HF, heart failure; VT, ventricular tachycardia; RVOR, right ventricular outflow tract; FU, follow-up.
Purkinje driver.
Inducibility testing was performed using the pacing protocol which induced VF prior to ablation. In the column ‘substrate’, the total epicardial RV surface was separated into an upper half (anterior) and a lower half (inferior).